Postmenopausal osteoporosis: patient choices and outcomes
MaturitasPublished 1 September 1995
Felicia Cosman, Jeri W. Nieves, J Walliser, Robert Lindsay
Citations8
SJR quartileQ1
SJR score1.22
SNIP1.23
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
This study underscores the need for an alternative to estrogen therapy which is equally effective and can be given orally for those in whom estrogen is either contraindicated or undesirable, and suggests that all three agents appear equally effective at maintaining or increasing BMD of the lumbar spine, while estrogen appeared more effective at keeping or increasing bone mineral density of the appendicular skeleton.
Abstract
These preliminary results suggest that all three agents appear equally effective at maintaining or increasing BMD of the lumbar spine, while estrogen appeared more effective at maintaining or increasing BMD of the appendicular skeleton. This study underscores the need for an alternative to estrogen therapy which is equally effective and can be given orally for those in whom estrogen is either contraindicated or undesirable.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
New England Journal of MedicineIntermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
956 Citations1990Nelson B. Watts, Steven T. Harris +14 more
New England Journal of MedicineEffect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal Osteoporosis
940 Citations1990T. Storm, Gorm Thamsborg +3 more
Etidronate therapy for postmenopausal osteoporosis results in significant increases in vertebral bone mineral content and, after approximately one year of treatment, a significant decrease in the rate of new vertebral fractures.
Journal of Clinical InvestigationChanges in Bone Mineral Density of the Proximal Femur and Spine with Aging
823 Citations1982B. Lawrence Riggs, Heinz W. Wahner +6 more
The data suggest the existence of two distinct syndromes: one form, "postmenopausal osteoporosis," is characterized by excessive and disproportionate trabecular bone loss, involves a small subset of women in the early postmenopausal period, and is associated with hip fractures or vertebral fractures or both.
The LancetPREVENTION OF SPINAL OSTEOPOROSIS IN OOPHORECTOMISED WOMEN
705 Citations1980Robert S. Lindsay, D.M. Hart +2 more
100 women who had taken part in a prospective controlled trial of oestrogen therapy for prevention of post-oophorectomy bone loss were reviewed after a median follow-up period of nine years.
Clinical Orthopaedics and Related ResearchOn Aging Bone Loss
546 Citations1982Richard B. Mazess
The findings suggest that the common assumption about a large ongoing loss of trabecular bone after menopause may be erroneous, as are the implications of the findings for calcium metabolism, anatomical correlations and fracture incidences.
Annals of Internal MedicinePostmenopausal Bone Loss Is Prevented by Treatment with Low-Dosage Estrogen with Calcium
534 Citations1987Bruce Ettinger, HARRY K. GENANT +1 more
Bone mass was measured prospectively in 73 women during the period immediately after menopause and after 2 years of follow-up to assess the protective effects of calcium supplements given alone or combined with low-dosage estrogen therapy.
The American Journal of MedicineFour-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy
355 Citations1993Steven T. Harris, Nelson B. Watts +7 more
MetabolismLong-term calcitonin therapy in postmenopausal osteoporosis
330 Citations1984Helen E. Gruber, Joel L. Ivey +5 more
Iliac crest bone biopsies showed a significantly greater percent total bone area in treated compared to control patients at 2 years, and a significantly decreased percent resorbing surface in treated patients when evaluated by paired difference from baseline.
BMJEvidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.
291 Citations1992John А. Kanis, Olof Johnell +8 more
Oestrogen, calcium, and calcitonins significantly decrease the risk of hip fracture, and short term intervention late in the natural course of osteoporosis may have significant effects on the incidence of hip fractures.
Calcified Tissue InternationalA critical review of bone mass and the risk of fractures in osteoporosis
275 Citations1990Philip D. Ross, James W. Davis +2 more
It is concluded that more emphasis should be given to the results of prospective studies, and that more attention should be paid to subject selection in all investigations, to reduce the level of confusion in the field and provide more clinically relevant information.
International Journal of Gynecology & ObstetricsEstrogen treatment of patients with established postmenopausal osteoporosis
254 Citations1991Robert Lindsay, Joyce Tohme
Estrogen therapy appears to be an effective therapy for patients with established osteoporosis and is associated with a significant increase in bone mass compatible with reduced skeletal turnover and activation frequency.
PubMedUterine activity in patients with cervical cerclage.
205 Citations1990Alfred G. Robichaux, C M Stedman +1 more
Bone and MineralSalmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome
110 Citations1992H. Rico, E. R. Hernández +2 more
Results show that calcitonin induced a significant reduction in postmenopausal osteoporotic vertebral fractures.
The Journal of Clinical Endocrinology & MetabolismCoherence Therapy Does Not Prevent Axial Bone Loss in Osteoporotic Women: A Preliminary Comparative Study
79 Citations1988Roberto Pacifici, Cynthia T. McMurtry +3 more
Preliminary results indicate that the ADFR regimen using phosphate and etidronate in doses of 1.5 g/day for 3 days and 400 mg/ day for 14 days, respectively, is not as effective as hormonal replacement in preventing trabecular bone loss in osteoporosis, nor it is any more effective than calcium supplementation alone.
MetabolismAging bone loss from the femur, spine, radius, and total skeleton
52 Citations1990John F. Aloia, A. Vaswani +2 more
Longitudinal studies confirmed that substantial bone loss begins only after menopause for the radius, whereas there is substantial premenopausal loss of bone from the lumbar spine, and there will be important implications for prevention of hip fractures.
Osteoporosis InternationalThe effect of treatment with calcitonin on vertebral fracture rate in osteoporosis
30 Citations1993P. Burckhardt, Bernard Burnand
Failure to allow for the initial prevalence of vertebral fractures at the individual level in therapeutic trials of calcitonin to treat osteoporosis and prevent new fractures might have contributed to the absence of a demonstrable benefit of the treatment in those studies.
Annals of Internal MedicineSalmon Calcitonin in the Treatment of Postmenopausal Osteoporosis
27 Citations1987Vahab Fatourechi, HUNTER HEATH
It is hoped that appropriate intervention will reduce morbidity and mortality resulting from vertebrae-related fractures in women with postmenopausal osteoporosis.
Calcified Tissue InternationalComparative assessment of bone mineral density of the forearm using single photon and dual X-ray absorptiometry
24 Citations1992Jeri W. Nieves, Felicia Cosman +2 more
It is concluded that overall, SPA forearm measurements in a population can be calibrated to DXA measurements if necessary, and that DXA forearm measurements are as predictive of the remainder of the skeleton as SPA measurements.